SCHEMBL708032

SCHEMBL708032

CC(C)(C)[Si](Br)(c1ccccc1)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.36
NR1H3 Q13133 2/20 0.36
ESR1 P03372 3/20 0.34
ESR2 Q92731 3/20 0.34
MAPK1 P28482 1/20 0.33
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
MAPT P10636 1/20 0.31
CYP2B6 P20813 1/20 0.31
ALDH1A1 P00352 3/20 0.31
TAAR1 Q96RJ0 2/20 0.31
ALOX15 P16050 1/20 0.31
SLC6A2 P23975 1/20 0.31
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30
ALOX12 P18054 1/20 0.30
ACHE P22303 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
ATM Q13315 1/20 0.30
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL705909 0.79 MAPK1 (0.39) NR1H2NR1H3ESR1ESR2MAPK1
SCHEMBL703364 0.79 ESR1 (0.34) NR1H2NR1H3ESR1ESR2MAPK1
SCHEMBL3526796 0.72 ESR1 (0.37) NR1H2NR1H3ESR1ESR2MAPK1
SCHEMBL29749402 0.72 ESR1 (0.37) NR1H2NR1H3ESR1ESR2MAPK1
SCHEMBL20328588 0.72 ESR1 (0.37) NR1H2NR1H3ESR1ESR2MAPK1
SCHEMBL3888384 0.72 ESR1 (0.37) NR1H2NR1H3ESR1ESR2MAPK1
SCHEMBL1203382 0.72 MAPK1 (0.33) ESR1ESR2MAPK1ALDH1A1ALOX15
SCHEMBL8381381 0.70 TAAR1 (0.37) NR1H2NR1H3ESR1ESR2MAPK1
SCHEMBL6013056 0.70 ESR1 (0.41) NR1H2NR1H3ESR1ESR2MAPK1
SCHEMBL988384 0.70 NR1H2 (0.48) NR1H2NR1H3ESR1ESR2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504697-A Cyclohexadiene derivative and preparation method thereof 博璞诺(上海)医药科技发展有限公司 2025-02-25 CN claimed
CN-107629069-B Preparation method of acetyl coenzyme A carboxylase inhibitor 中国药科大学 2023-01-24 CN claimed
CN-119504697-A Cyclohexadiene derivative and preparation method thereof 博璞诺(上海)医药科技发展有限公司 2025-02-25 CN disclosed
CN-107629069-B Preparation method of acetyl coenzyme A carboxylase inhibitor 中国药科大学 2023-01-24 CN disclosed
CN-104974184-B preparation of silazane Compounds 信越化学工业株式会社 2019-12-06 CN disclosed
CN-104725365-B Hepatitis C virus inhibitors and its application 南京圣和药业股份有限公司 2019-02-26 CN disclosed
EP-2930177-B1 PREPARATION OF SILAZANE COMPOUND SHINETSU CHEMICAL CO (JP) 2018-04-25 EP disclosed
US-9416147-B2 Preparation of silazane compound SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-08-16 US disclosed
EP-2508504-B1 PROCESS FOR PREPARATION OF CYCLOALKANEDICARBOXYLIC ACID MONOESTERS SUMITOMO CHEMICAL CO (JP) 2016-04-13 EP disclosed
EP-2930177-A1 Preparation of silazane compound Shin-Etsu Chemical Co., Ltd. (JP) 2015-10-14 EP disclosed
US-20150284414-A1 PREPARATION OF SILAZANE COMPOUND SHIN-ETSU CHEMICAL CO., LTD. (JP) 2015-10-08 US disclosed
EP-1000937-A1 PROCESS FOR PRODUCING 4-ALKOXYCARBONYL-2-OXAZOLIDINONE COMPOUNDS UBE INDUSTRIES LIMITED (JP) 2000-05-17 EP disclosed
US-5691319-A ANTICARCINOGENIC AGENTS SANKYO COMPANY, LIMITED (JP) 1997-11-25 US disclosed
US-5663342-A GLUCOSIDASE INHIBITORS, ANTIVIRAL, ANTI-HIV G. D. SEARLE & CO. (US) 1997-09-02 US disclosed
US-5612480-A GLUCOSIDASE INHIBITORS G. D. SEARLE & CO. (US) 1997-03-18 US disclosed
US-5595981-A GLUCOSIDASE INHIBITOR, VIRICIDE, NOJIRIMYCIN DERIVATIVES G.D. SEARLE & CO. (US) 1997-01-21 US disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP disclosed
US-5451679-A GLUCOSIDASE INHIBITORS, VIRICIDES G. D. SEARLE & CO. (US) 1995-09-19 US disclosed
WO-1995024392-A1 2-CHLORO AND 2-BROMO DERIVATIVES OF 1,5-IMINOSUGARS G. D. SEARLE & CO. (US) 1995-09-14 WO disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284414-A1 PREPARATION OF SILAZANE COMPOUND SLTM, SKP2, BCAT2 NR1H2 4366/4885NR1H3 4242/4885ESR1 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.